首页 > 最新文献

European journal of gynaecological oncology最新文献

英文 中文
Symptomatic women experience long waits for endometrial cancer diagnosis and treatment in Brazil 在巴西,有症状的妇女在子宫内膜癌的诊断和治疗方面经历了漫长的等待
4区 医学 Q4 OBSTETRICS & GYNECOLOGY Pub Date : 2023-01-01 DOI: 10.22514/ejgo.2023.063
The aim of this study was to assess the elapsed time for symptomatic women with endometrial carcinoma to achieve diagnosis and treatment and its impact on staging and survival. A cohort study was carried out with 430 women divided into in two groups: “Type I” (n = 289, endometrioid carcinoma grade 1 or 2); “Type II” (n = 141, nonendometrioid, endometrioid carcinoma grade 3, or carcinosarcoma). Clinical information, diagnostic methods, histology, staging, and time elapsed between symptoms-diagnosis-treatment were considered. Descriptive, survival, and regression analyses were performed. The symptom-to-diagnosis interval was 284 and 249 days in Types I and II (p = 0.014), with only 30% getting a diagnosis within 90 days. The diagnosis-to-treatment interval was shorter for Type II (100 vs. 123 days for Type I; p = 0.001). Only 12.5% of Type I and 22.7% of Type II started treatment within 60 days after diagnosis. There was no association between symptom-to-diagnosis interval and staging (p = 0.377). The symptom-to-treatment interval did not change the overall survival for Type I and had a paradoxical effect for Type II, with greater overall survival associated with a longer elapsed time (p = 0.003). Symptomatic Brazilian women with endometrial carcinomas showed very long wait times for diagnosis and treatment, and less than 23% started treatment within the regulatory period of 60 days. This critical situation does not exhibit any clear effect on cancer staging or overall survival, possibly counterbalanced by the faster care of patients with a poor prognosis, such as those with Type II endometrial carcinomas.
本研究的目的是评估有症状的子宫内膜癌妇女获得诊断和治疗的时间及其对分期和生存的影响。一项队列研究将430名女性分为两组:“I型”(289名,1级或2级子宫内膜样癌);“II型”(141名,非子宫内膜样癌、3级子宫内膜样癌或癌肉瘤)。临床信息、诊断方法、组织学、分期和症状-诊断-治疗之间的时间间隔被考虑在内。进行描述性分析、生存分析和回归分析。I型和II型患者从症状到诊断的时间间隔分别为284天和249天(p = 0.014),只有30%的患者在90天内得到诊断。II型从诊断到治疗的间隔时间较短(100天vs. 123天,p = 0.001)。只有12.5%的I型和22.7%的II型患者在诊断后60天内开始治疗。从症状到诊断的时间间隔与分期无相关性(p = 0.377)。症状到治疗的时间间隔并没有改变I型患者的总生存期,但对II型患者却有矛盾的影响,总生存期越长,时间越长(p = 0.003)。有症状的巴西子宫内膜癌妇女的诊断和治疗等待时间很长,不到23%的人在规定的60天内开始治疗。这种危急情况对癌症分期或总生存期没有明显的影响,可能通过对预后较差的患者(如II型子宫内膜癌患者)的更快护理来抵消。
{"title":"Symptomatic women experience long waits for endometrial cancer diagnosis and treatment in Brazil","authors":"","doi":"10.22514/ejgo.2023.063","DOIUrl":"https://doi.org/10.22514/ejgo.2023.063","url":null,"abstract":"The aim of this study was to assess the elapsed time for symptomatic women with endometrial carcinoma to achieve diagnosis and treatment and its impact on staging and survival. A cohort study was carried out with 430 women divided into in two groups: “Type I” (n = 289, endometrioid carcinoma grade 1 or 2); “Type II” (n = 141, nonendometrioid, endometrioid carcinoma grade 3, or carcinosarcoma). Clinical information, diagnostic methods, histology, staging, and time elapsed between symptoms-diagnosis-treatment were considered. Descriptive, survival, and regression analyses were performed. The symptom-to-diagnosis interval was 284 and 249 days in Types I and II (p = 0.014), with only 30% getting a diagnosis within 90 days. The diagnosis-to-treatment interval was shorter for Type II (100 vs. 123 days for Type I; p = 0.001). Only 12.5% of Type I and 22.7% of Type II started treatment within 60 days after diagnosis. There was no association between symptom-to-diagnosis interval and staging (p = 0.377). The symptom-to-treatment interval did not change the overall survival for Type I and had a paradoxical effect for Type II, with greater overall survival associated with a longer elapsed time (p = 0.003). Symptomatic Brazilian women with endometrial carcinomas showed very long wait times for diagnosis and treatment, and less than 23% started treatment within the regulatory period of 60 days. This critical situation does not exhibit any clear effect on cancer staging or overall survival, possibly counterbalanced by the faster care of patients with a poor prognosis, such as those with Type II endometrial carcinomas.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136115277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study on the intake and efficacy of nab-paclitaxel in patients with advanced cervical cancer nab-紫杉醇在晚期宫颈癌患者中的摄入量及疗效研究
4区 医学 Q4 OBSTETRICS & GYNECOLOGY Pub Date : 2023-01-01 DOI: 10.22514/ejgo.2023.061
Cervical cancer is the second most common malignant tumor in women. This study aimed to investigate the intake and effect of nab-paclitaxel in chemotherapy for patients with advanced cervical cancer, to collect more evidence for clinical medication. A total of 96 patients with advanced cervical cancer who received chemotherapy treatment in Wuhan Third Hospital from July 2021 to July 2022 were randomly divided into observation group (treated with nab-paclitaxel + cisplatin) and control group (treated with paclitaxel + cisplatin) by envelope method. The short-term efficacy, tumor markers, immune function indicators, adverse reactions and quality of life of both groups were observed and compared with each other. After treatment, serum tumor markers were notably decreased, while cluster of differentiation 4 (CD4)+ and CD4+/cluster of differentiation 8 (CD8)+ were clearly increased in both groups. The observation group showed the improvement effect of each index in a statistically significant manner (p < 0.05) than the control group. The effective disease control rate of observation group was higher than that of the control group while the incidence of treatment-related adverse reactions in the observation group was higher than that of the control group. The observation group indicated improved effective rate of Karnofsky Performance Scale (KPS) than the control group (p < 0.05). In conclusion, nab-paclitaxel has significant advantages in chemotherapy for patients suffering from advanced cervical cancer, which can strengthen immune function, improve the effectiveness of disease control, and promote the improvement of functional status.
子宫颈癌是女性中第二常见的恶性肿瘤。本研究旨在探讨nab-紫杉醇在晚期宫颈癌患者化疗中的摄入量及疗效,为临床用药提供更多依据。选取武汉市第三医院2021年7月至2022年7月期间接受化疗的晚期宫颈癌患者96例,采用包膜法随机分为观察组(nab-紫杉醇+顺铂治疗)和对照组(紫杉醇+顺铂治疗)。观察两组患者的近期疗效、肿瘤标志物、免疫功能指标、不良反应及生活质量,并进行比较。治疗后,两组患者血清肿瘤标志物均明显降低,CD4+和CD4+/ CD8 +均明显升高。观察组各指标改善效果均有统计学意义(p <0.05)。观察组疾病有效控制率高于对照组,治疗相关不良反应发生率高于对照组。观察组的Karnofsky绩效量表(KPS)有效率较对照组提高(p <0.05)。综上所述,nab-紫杉醇在晚期宫颈癌患者化疗中具有显著优势,可增强免疫功能,提高疾病控制效果,促进功能状态改善。
{"title":"Study on the intake and efficacy of nab-paclitaxel in patients with advanced cervical cancer","authors":"","doi":"10.22514/ejgo.2023.061","DOIUrl":"https://doi.org/10.22514/ejgo.2023.061","url":null,"abstract":"Cervical cancer is the second most common malignant tumor in women. This study aimed to investigate the intake and effect of nab-paclitaxel in chemotherapy for patients with advanced cervical cancer, to collect more evidence for clinical medication. A total of 96 patients with advanced cervical cancer who received chemotherapy treatment in Wuhan Third Hospital from July 2021 to July 2022 were randomly divided into observation group (treated with nab-paclitaxel + cisplatin) and control group (treated with paclitaxel + cisplatin) by envelope method. The short-term efficacy, tumor markers, immune function indicators, adverse reactions and quality of life of both groups were observed and compared with each other. After treatment, serum tumor markers were notably decreased, while cluster of differentiation 4 (CD4)+ and CD4+/cluster of differentiation 8 (CD8)+ were clearly increased in both groups. The observation group showed the improvement effect of each index in a statistically significant manner (p < 0.05) than the control group. The effective disease control rate of observation group was higher than that of the control group while the incidence of treatment-related adverse reactions in the observation group was higher than that of the control group. The observation group indicated improved effective rate of Karnofsky Performance Scale (KPS) than the control group (p < 0.05). In conclusion, nab-paclitaxel has significant advantages in chemotherapy for patients suffering from advanced cervical cancer, which can strengthen immune function, improve the effectiveness of disease control, and promote the improvement of functional status.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136115280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Conservative surgical treatment of uterine fibroids in women of childbearing age 育龄妇女子宫肌瘤的保守手术治疗
4区 医学 Q4 OBSTETRICS & GYNECOLOGY Pub Date : 2023-01-01 DOI: 10.22514/ejgo.2023.053
Uterine fibroids are benign gynecologic tumors, and women aged between 30 to 50 years are known to have a high incidence of uterine fibroids. A growing number of pharmacotherapies and minimally invasive organ-preserving treatments have been designed and conducted over the past few years. However, there has not been any therapeutic drugs exhibiting an ideal therapeutic effect and low recurrence rate, such that the surgical treatment continues to be primarily employed in the actual clinical treatment. In general, surgical treatment has been performed as the organ- and fertility-preserving hysteroscopic or laparoscopic resections of the fibroids. Minimally invasive surgical equipment (e.g., hysteroscopy, traditional porous laparoscopy, trans-umbilical laparoscopy, transvaginal laparoscopy, as well as robot-assisted laparoscopy) has been extensively applied to clinical treatment. Compared with traditional laparotomy, minimally invasive surgical equipment is characterized by minimally invasive surgery, high efficiency and safety. As medical technology has been leaping forward, interventional therapy and radiofrequency ablation can also be employed for treating uterine fibroids. In accordance with the research progress worldwide, the current situation, limitations, and advantages of the treatment of uterine fibroids in patients with fertility requirements are reviewed in this study.
子宫肌瘤是妇科良性肿瘤,已知30 ~ 50岁的女性是子宫肌瘤的高发年龄段。在过去的几年中,越来越多的药物治疗和微创器官保存治疗被设计和实施。然而,目前还没有一种治疗药物表现出理想的治疗效果和低复发率,因此在实际临床治疗中仍然主要采用手术治疗。一般来说,手术治疗已作为保留器官和生育能力的宫腔镜或腹腔镜切除肌瘤。微创手术设备(如宫腔镜、传统的多孔腹腔镜、经脐腹腔镜、经阴道腹腔镜以及机器人辅助腹腔镜)已广泛应用于临床治疗。与传统剖腹手术相比,微创手术设备具有手术微创、高效、安全的特点。随着医疗技术的突飞猛进,介入治疗和射频消融也可用于治疗子宫肌瘤。根据国内外研究进展,本文综述了有生育需求的患者子宫肌瘤治疗的现状、局限性及优势。
{"title":"Conservative surgical treatment of uterine fibroids in women of childbearing age","authors":"","doi":"10.22514/ejgo.2023.053","DOIUrl":"https://doi.org/10.22514/ejgo.2023.053","url":null,"abstract":"Uterine fibroids are benign gynecologic tumors, and women aged between 30 to 50 years are known to have a high incidence of uterine fibroids. A growing number of pharmacotherapies and minimally invasive organ-preserving treatments have been designed and conducted over the past few years. However, there has not been any therapeutic drugs exhibiting an ideal therapeutic effect and low recurrence rate, such that the surgical treatment continues to be primarily employed in the actual clinical treatment. In general, surgical treatment has been performed as the organ- and fertility-preserving hysteroscopic or laparoscopic resections of the fibroids. Minimally invasive surgical equipment (e.g., hysteroscopy, traditional porous laparoscopy, trans-umbilical laparoscopy, transvaginal laparoscopy, as well as robot-assisted laparoscopy) has been extensively applied to clinical treatment. Compared with traditional laparotomy, minimally invasive surgical equipment is characterized by minimally invasive surgery, high efficiency and safety. As medical technology has been leaping forward, interventional therapy and radiofrequency ablation can also be employed for treating uterine fibroids. In accordance with the research progress worldwide, the current situation, limitations, and advantages of the treatment of uterine fibroids in patients with fertility requirements are reviewed in this study.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136115281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the relationship of the amount of ascites as measured quantitatively using computed tomography with chemotherapy toxicity in patients with ovarian cancer 评价卵巢癌患者用计算机断层扫描定量测量的腹水量与化疗毒性的关系
4区 医学 Q4 OBSTETRICS & GYNECOLOGY Pub Date : 2023-01-01 DOI: 10.22514/ejgo.2023.078
In this study, it was planned to investigate the effects of ascites and sarcopenia on treatment toxicity, disease free survival (DFS) and disease specific survival (DSS) times in a population of patients with stage 3–4 ovarian cancer. In this retrospective study that include 80 patients treated and followed-up for advanced stage ovarian cancer in a university hospital between 2012–2019, ascites volumes and sarcopenia indices of the patients were calculated by computed tomography from medical patient records, and their clinico-pathologic characteristics as well as laboratory variables were reviewed. The median survival was 30.10 ± 2.85 months for the patients with ascites and 54.26 ± 4.16 months without ascites (p < 0.001). The duration of DSS was found to be negatively affected in patients with ascites (Hazard Ratio (HR): 3.048), prognostic nutritional index (PNI) <47.5 (HR: 2.528), platelet (PLT) >338,000 (HR: 1.936), lactate dehydrogenase (LDH) value >320 (HR: 1.624), albumin value <4 (HR: 1.849). When factors that are found to have a significant relationship with DSS were assessed according to multivariate Cox regression analysis, the presence of ascites was identified as an independent risk factor associated with DSS (p: 0.004). The risk of developing grade 2 or 3 neutropenia, anemia and thrombocytopenia is significantly increased following the first chemotherapy course in patients with ascites when compared to those without ascites (p: 0.006). The presence of ascites in patients with ovarian cancer is a risk factor associated with chemotherapy toxicity and reduced survival.
在这项研究中,计划探讨腹水和肌肉减少症对3-4期卵巢癌患者治疗毒性、无病生存期(DFS)和疾病特异性生存期(DSS)时间的影响。回顾性研究纳入2012-2019年在某大学附属医院接受治疗并随访的80例晚期卵巢癌患者,利用病历资料,通过计算机断层扫描计算患者的腹水体积和肌肉减少指数,并对其临床病理特征和实验室变量进行分析。腹水患者中位生存期为30.10±2.85个月,无腹水患者中位生存期为54.26±4.16个月(p <0.001)。发现腹水患者的DSS持续时间(风险比(HR): 3.048)、预后营养指数(PNI) & 47.5 (HR: 2.528)、血小板(PLT) & 33.8万(HR: 1.936)、乳酸脱氢酶(LDH)值>320 (HR: 1.624)、白蛋白值<4 (HR: 1.849)均受到负面影响。根据多变量Cox回归分析评估与DSS有显著关系的因素时,腹水的存在被确定为与DSS相关的独立危险因素(p: 0.004)。与没有腹水的患者相比,腹水患者在第一次化疗后发生2级或3级中性粒细胞减少症、贫血和血小板减少症的风险显著增加(p: 0.006)。卵巢癌患者腹水的存在是与化疗毒性和降低生存率相关的危险因素。
{"title":"Evaluation of the relationship of the amount of ascites as measured quantitatively using computed tomography with chemotherapy toxicity in patients with ovarian cancer","authors":"","doi":"10.22514/ejgo.2023.078","DOIUrl":"https://doi.org/10.22514/ejgo.2023.078","url":null,"abstract":"In this study, it was planned to investigate the effects of ascites and sarcopenia on treatment toxicity, disease free survival (DFS) and disease specific survival (DSS) times in a population of patients with stage 3–4 ovarian cancer. In this retrospective study that include 80 patients treated and followed-up for advanced stage ovarian cancer in a university hospital between 2012–2019, ascites volumes and sarcopenia indices of the patients were calculated by computed tomography from medical patient records, and their clinico-pathologic characteristics as well as laboratory variables were reviewed. The median survival was 30.10 ± 2.85 months for the patients with ascites and 54.26 ± 4.16 months without ascites (p < 0.001). The duration of DSS was found to be negatively affected in patients with ascites (Hazard Ratio (HR): 3.048), prognostic nutritional index (PNI) <47.5 (HR: 2.528), platelet (PLT) >338,000 (HR: 1.936), lactate dehydrogenase (LDH) value >320 (HR: 1.624), albumin value <4 (HR: 1.849). When factors that are found to have a significant relationship with DSS were assessed according to multivariate Cox regression analysis, the presence of ascites was identified as an independent risk factor associated with DSS (p: 0.004). The risk of developing grade 2 or 3 neutropenia, anemia and thrombocytopenia is significantly increased following the first chemotherapy course in patients with ascites when compared to those without ascites (p: 0.006). The presence of ascites in patients with ovarian cancer is a risk factor associated with chemotherapy toxicity and reduced survival.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"125 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136366311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tumor growth inhibition and tumor specific immunity enhancement in endometrial carcinoma by high intensity focused ultrasound 高强度聚焦超声对子宫内膜癌肿瘤生长抑制及肿瘤特异性免疫增强作用的研究
4区 医学 Q4 OBSTETRICS & GYNECOLOGY Pub Date : 2023-01-01 DOI: 10.22514/ejgo.2023.085
Endometrial carcinoma (EC) is a type of epithelial malignancy prevalent in about 8% of the total malignancies in women. Development of new treatment methods is vital for improving the prognosis of endometrial cancer. High Intensity Focused Ultrasound (HIFU) is a safe method for oncological treatment with low complication rate. However, EC treatment by HIFU is rarely reported and its mechanism is unclear. Herein, the effects of HIFU on EC progression were detected. Data confirmed the inhibition of EC tumor growth in mice by HIFU. Moreover, HIFU inhibited the EC tumor apoptosis. It down-regulated the Treg cell production and enhanced the tumor-specific cytotoxicity. It restrained the Janus kinase/Signal transducer and activator of transcription 3 (JAK/STAT3) pathway in viv
子宫内膜癌(EC)是一种常见的上皮恶性肿瘤,约占女性恶性肿瘤总数的8%。发展新的治疗方法对改善子宫内膜癌的预后至关重要。高强度聚焦超声(HIFU)是一种安全、低并发症的肿瘤治疗方法。然而,HIFU治疗EC的报道很少,其机制尚不清楚。本研究检测了HIFU对EC进展的影响。数据证实HIFU对小鼠EC肿瘤生长有抑制作用。HIFU对EC肿瘤的凋亡有抑制作用。下调Treg细胞的产生,增强肿瘤特异性细胞毒性。在体外抑制Janus kinase/Signal transducer and activator of transcription 3 (JAK/STAT3)通路
{"title":"Tumor growth inhibition and tumor specific immunity enhancement in endometrial carcinoma by high intensity focused ultrasound","authors":"","doi":"10.22514/ejgo.2023.085","DOIUrl":"https://doi.org/10.22514/ejgo.2023.085","url":null,"abstract":"Endometrial carcinoma (EC) is a type of epithelial malignancy prevalent in about 8% of the total malignancies in women. Development of new treatment methods is vital for improving the prognosis of endometrial cancer. High Intensity Focused Ultrasound (HIFU) is a safe method for oncological treatment with low complication rate. However, EC treatment by HIFU is rarely reported and its mechanism is unclear. Herein, the effects of HIFU on EC progression were detected. Data confirmed the inhibition of EC tumor growth in mice by HIFU. Moreover, HIFU inhibited the EC tumor apoptosis. It down-regulated the Treg cell production and enhanced the tumor-specific cytotoxicity. It restrained the Janus kinase/Signal transducer and activator of transcription 3 (JAK/STAT3) pathway in viv","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136368237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GINS2 regulates epithelial mesenchymal transformation and cell cycle in endometrial carcinoma by stimulating ERK/MAPK signaling GINS2通过刺激ERK/MAPK信号传导调节子宫内膜癌上皮间质转化和细胞周期
4区 医学 Q4 OBSTETRICS & GYNECOLOGY Pub Date : 2023-01-01 DOI: 10.22514/ejgo.2023.067
Endometrial cancer (EC) is one of the three main gynecological cancers. Identifying new therapeutic targets and further elucidating the molecular mechanisms of EC tumorigenesis have important implications for women’s health. The Go-Ichi-Ni-San (GINS) family, which includes four subunits (GINS1–4), has specific functions in DNA replication and cell cycle. The Cancer Genome Atlas (TCGA) data showed that GINS2 transcription level is upregulated in endometrial cancer tissue. However, the possible role of GINS2 in EC progression is still unknown. Herein, we explored the role of GINS2 in EC. We noticed that GINS2 was overexpressed in EC cells. GINS2 knockdown suppressed the proliferation of EC cells and induced cell cycle arrest. We further noticed that GINS2 knockdown restrained the Epithelial mesenchymal transformation (EMT) of EC cells. Mechanically, its downregulation suppressed the extracellular regulated protein kinase (ERK)/Microtubule-Associated Protein Kinase (MAPK) pathway, thereby suppressing EC progression. Thus, GINS2 has the potential to act as a therapeutic target for EC.
子宫内膜癌是妇科三大肿瘤之一。寻找新的治疗靶点并进一步阐明EC肿瘤发生的分子机制对女性健康具有重要意义。Go-Ichi-Ni-San (GINS)家族包括4个亚基(GINS1-4),在DNA复制和细胞周期中具有特定功能。Cancer Genome Atlas (TCGA)数据显示,GINS2转录水平在子宫内膜癌组织中上调。然而,GINS2在EC进展中的可能作用仍然未知。在此,我们探讨了GINS2在EC中的作用。我们注意到GINS2在EC细胞中过表达。GINS2敲除抑制EC细胞增殖,诱导细胞周期阻滞。我们进一步注意到,GINS2敲低抑制了EC细胞的上皮间充质转化(Epithelial mesenchymal transformation, EMT)。机械上,其下调抑制了细胞外调节蛋白激酶(ERK)/微管相关蛋白激酶(MAPK)途径,从而抑制了EC的进展。因此,GINS2有可能作为EC的治疗靶点。
{"title":"GINS2 regulates epithelial mesenchymal transformation and cell cycle in endometrial carcinoma by stimulating ERK/MAPK signaling","authors":"","doi":"10.22514/ejgo.2023.067","DOIUrl":"https://doi.org/10.22514/ejgo.2023.067","url":null,"abstract":"Endometrial cancer (EC) is one of the three main gynecological cancers. Identifying new therapeutic targets and further elucidating the molecular mechanisms of EC tumorigenesis have important implications for women’s health. The Go-Ichi-Ni-San (GINS) family, which includes four subunits (GINS1–4), has specific functions in DNA replication and cell cycle. The Cancer Genome Atlas (TCGA) data showed that GINS2 transcription level is upregulated in endometrial cancer tissue. However, the possible role of GINS2 in EC progression is still unknown. Herein, we explored the role of GINS2 in EC. We noticed that GINS2 was overexpressed in EC cells. GINS2 knockdown suppressed the proliferation of EC cells and induced cell cycle arrest. We further noticed that GINS2 knockdown restrained the Epithelial mesenchymal transformation (EMT) of EC cells. Mechanically, its downregulation suppressed the extracellular regulated protein kinase (ERK)/Microtubule-Associated Protein Kinase (MAPK) pathway, thereby suppressing EC progression. Thus, GINS2 has the potential to act as a therapeutic target for EC.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"148 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136115073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Application of health education based on the integrated theory of health behavior change in the pelvic floor rehabilitation of patients with cervical cancer after radical surgery 基于健康行为改变综合理论的健康教育在宫颈癌根治术后盆底康复中的应用
4区 医学 Q4 OBSTETRICS & GYNECOLOGY Pub Date : 2023-01-01 DOI: 10.22514/ejgo.2023.062
To analyze the effect of applying health education based on the integrated theory of health behavior change in the pelvic floor rehabilitation of patients with cervical cancer after radical surgery. We recruited 130 patients with cervical cancer who underwent gynecological surgery in our hospital between the 01 February 2021 and the 01 March 2022. According to the random number table method, the patients were divided into a control group and an observation group (65 cases per group). The control group received routine health education, while the observation group received health education based on the integrated theory of health behavior change. We compared the two groups with regards to pelvic floor function, quality-of-life, and psychological status before and after intervention by analyzing PFDI-20 (Pelvic Floor Distress Inventory Questionnaire-20), PFIQ-7 (Pelvic Floor Impact Questionnaire-7), HAMA (Hamilton Anxiety Scale) and HAMD (Hamilton Depression Scale) questionnaires, treatment compliance and nursing satisfaction. After intervention, the PFDI-20 scores and total scores of patients in the observation group were lower than those in the control group (p < 0.05). The PFIQ-7 scores and total scores of patients in the observation group were lower than those in the control group (p < 0.05). The HAMA and HAMD scores in the observation group were significantly lower than those in the control group (p < 0.05). The treatment compliance and nursing satisfaction rate of patients in the observation group were higher than those in the control group (p < 0.05). Health education based on the integrated theory of health behavior change can improve pelvic floor muscle strength, the quality-of-life, and the treatment compliance of patients after radical surgery for cervical cancer. In addition, this strategy can alleviate anxiety and depression, and improve nursing satisfaction and is worthy of wider clinical application.
分析基于健康行为改变综合理论的健康教育在宫颈癌根治术后盆底康复中的应用效果。我们招募了130例于2021年2月1日至2022年3月1日在我院接受妇科手术的宫颈癌患者。按随机数字表法将患者分为对照组和观察组,每组65例。对照组接受常规健康教育,观察组接受基于健康行为改变综合理论的健康教育。通过分析PFDI-20(盆底困扰问卷-20)、PFIQ-7(盆底影响问卷-7)、HAMA(汉密尔顿焦虑量表)和HAMD(汉密尔顿抑郁量表)问卷、治疗依从性和护理满意度,比较两组患者干预前后的盆底功能、生活质量和心理状态。干预后,观察组患者PFDI-20评分及总分均低于对照组(p <0.05)。观察组患者PFIQ-7评分及总分均低于对照组(p <0.05)。观察组患者HAMA、HAMD评分均显著低于对照组(p <0.05)。观察组患者的治疗依从性和护理满意率均高于对照组(p <0.05)。基于健康行为改变综合理论的健康教育可提高宫颈癌根治术后盆底肌力,改善患者的生活质量和治疗依从性。此外,该策略可以缓解焦虑和抑郁,提高护理满意度,值得在临床推广应用。
{"title":"Application of health education based on the integrated theory of health behavior change in the pelvic floor rehabilitation of patients with cervical cancer after radical surgery","authors":"","doi":"10.22514/ejgo.2023.062","DOIUrl":"https://doi.org/10.22514/ejgo.2023.062","url":null,"abstract":"To analyze the effect of applying health education based on the integrated theory of health behavior change in the pelvic floor rehabilitation of patients with cervical cancer after radical surgery. We recruited 130 patients with cervical cancer who underwent gynecological surgery in our hospital between the 01 February 2021 and the 01 March 2022. According to the random number table method, the patients were divided into a control group and an observation group (65 cases per group). The control group received routine health education, while the observation group received health education based on the integrated theory of health behavior change. We compared the two groups with regards to pelvic floor function, quality-of-life, and psychological status before and after intervention by analyzing PFDI-20 (Pelvic Floor Distress Inventory Questionnaire-20), PFIQ-7 (Pelvic Floor Impact Questionnaire-7), HAMA (Hamilton Anxiety Scale) and HAMD (Hamilton Depression Scale) questionnaires, treatment compliance and nursing satisfaction. After intervention, the PFDI-20 scores and total scores of patients in the observation group were lower than those in the control group (p < 0.05). The PFIQ-7 scores and total scores of patients in the observation group were lower than those in the control group (p < 0.05). The HAMA and HAMD scores in the observation group were significantly lower than those in the control group (p < 0.05). The treatment compliance and nursing satisfaction rate of patients in the observation group were higher than those in the control group (p < 0.05). Health education based on the integrated theory of health behavior change can improve pelvic floor muscle strength, the quality-of-life, and the treatment compliance of patients after radical surgery for cervical cancer. In addition, this strategy can alleviate anxiety and depression, and improve nursing satisfaction and is worthy of wider clinical application.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"88 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136115077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molybdenum target X-ray examination and multimodality MRI in the diagnosis of breast cancer 钼靶x线检查与多模态MRI在乳腺癌诊断中的价值
4区 医学 Q4 OBSTETRICS & GYNECOLOGY Pub Date : 2023-01-01 DOI: 10.22514/ejgo.2023.064
Breast cancer is one of the most common malignant diseases, with a high mortality rate, affecting mostly females. This study aims to assess the diagnostic value of Molybdenum target X-ray examination and multimodality Magnetic Resonance Imaging (MRI) in breast cancer diagnosis. A total of 60 patients with suspected breast cancer were screened and included in the study. All patients underwent Molybdenum target X-ray and multimodality MRI, and the results were compared to pathological examination, which served as the reference standard for evaluating the diagnostic efficacy of the different screening methods. Molybdenum target X-ray examination identified 19 positive cases and 41 negative cases. Comparatively, multimodality MRI detected 43 positive cases and 17 negative cases. Compared to Molybdenum target X-ray, multimodality MRI demonstrated higher diagnostic accuracy, specificity, and sensitivity. Further analysis revealed that among the 45 positive patients, 13 were classified as stage 1, 20 as stage 2, 9 as stage 3, and 3 as stage 4. The pathological types were categorized as invasive ductal carcinoma, intraductal carcinoma, and ductal carcinoma in situ, with 25, 6 and 14 cases, respectively. Intraductal carcinoma exhibited higher levels of enhancement rate and signal enhancement ratio, as well as shorter peak time, compared to the other two types. No significant difference was observed between invasive ductal carcinoma and ductal carcinoma in situ. In the clinical diagnosis of breast cancer, multimodality MRI examination proves to be more comprehensive and accurate in determining the tumor’s nature and the type of disease, with significant clinical value in the field.
乳腺癌是最常见的恶性疾病之一,死亡率高,主要影响女性。本研究旨在探讨钼靶x线检查和多模态磁共振成像(MRI)在乳腺癌诊断中的诊断价值。共有60名疑似乳腺癌患者接受了筛查,并纳入了这项研究。所有患者均行钼靶x线及多模态MRI检查,并与病理检查结果进行比较,作为评价不同筛查方法诊断效果的参考标准。钼靶x线检查阳性19例,阴性41例。多模态MRI阳性43例,阴性17例。与钼靶x线相比,多模态MRI具有更高的诊断准确性、特异性和敏感性。进一步分析显示,在45例阳性患者中,1期13例,2期20例,3期9例,4期3例。病理类型分为浸润性导管癌、导管内癌和导管原位癌,分别为25例、6例和14例。与其他两种类型相比,导管内癌表现出更高水平的增强率和信号增强比,峰值时间更短。浸润性导管癌与原位导管癌之间无显著性差异。在乳腺癌的临床诊断中,MRI多模态检查对肿瘤性质和疾病类型的判断更为全面和准确,具有重要的临床价值。
{"title":"Molybdenum target X-ray examination and multimodality MRI in the diagnosis of breast cancer","authors":"","doi":"10.22514/ejgo.2023.064","DOIUrl":"https://doi.org/10.22514/ejgo.2023.064","url":null,"abstract":"Breast cancer is one of the most common malignant diseases, with a high mortality rate, affecting mostly females. This study aims to assess the diagnostic value of Molybdenum target X-ray examination and multimodality Magnetic Resonance Imaging (MRI) in breast cancer diagnosis. A total of 60 patients with suspected breast cancer were screened and included in the study. All patients underwent Molybdenum target X-ray and multimodality MRI, and the results were compared to pathological examination, which served as the reference standard for evaluating the diagnostic efficacy of the different screening methods. Molybdenum target X-ray examination identified 19 positive cases and 41 negative cases. Comparatively, multimodality MRI detected 43 positive cases and 17 negative cases. Compared to Molybdenum target X-ray, multimodality MRI demonstrated higher diagnostic accuracy, specificity, and sensitivity. Further analysis revealed that among the 45 positive patients, 13 were classified as stage 1, 20 as stage 2, 9 as stage 3, and 3 as stage 4. The pathological types were categorized as invasive ductal carcinoma, intraductal carcinoma, and ductal carcinoma in situ, with 25, 6 and 14 cases, respectively. Intraductal carcinoma exhibited higher levels of enhancement rate and signal enhancement ratio, as well as shorter peak time, compared to the other two types. No significant difference was observed between invasive ductal carcinoma and ductal carcinoma in situ. In the clinical diagnosis of breast cancer, multimodality MRI examination proves to be more comprehensive and accurate in determining the tumor’s nature and the type of disease, with significant clinical value in the field.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"2014 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136115278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of bone health in breast cancer patients with germline pathogenic 种系致病性乳腺癌患者骨健康的评价
4区 医学 Q4 OBSTETRICS & GYNECOLOGY Pub Date : 2023-01-01 DOI: 10.22514/ejgo.2023.090
Patients with breast cancer (BC) have an increased risk of bone loss due to both the cancer itself and the side effects of antineoplastic therapies. This study evaluated the bone health of survivors of BC with germline pathogenic variants (PVs). This is a retrospective cross-sectional study. We identified 165 BC patients in whom PVs in BC susceptibility genes were diagnosed between February 2017 and December 2022 at our breast health center in Acibadem Altunizade Hospital. Only 80 patients underwent dual-energy X-ray absorptiometry (DXA) at the time of diagnosis. The median patient age was 44 years. Of 80 patients, 47% had (n = 38) had BRCA1 and BRCA2, while the remaining 53% (n = 42) had other PVs, which we refer to as non-BRCA. Risk-reducing bilateral salpingo-oophorectomy (RRBSO) was performed in 21 patients with BRCA and 6 patients with non-BRCA PVs patients (p < 0.001). At the 68-months follow up period, a total of 53% had osteopenia, and 11% had osteoporosis. According to the mutation type, among patients with BRCA1 and BRCA2, 47% exhibited osteopenia and 11% had osteoporosis. In non-BRCA, 57% had osteopenia and 12% had osteoporosis (p > 0.05). In this study, we showed that patients with BRCA and non-BRCA mutations have similar rates of osteopenia and osteoporosis. This is particularly important for non-BRCA mutation carriers, because there is insufficient data on this subject.
由于癌症本身和抗肿瘤治疗的副作用,乳腺癌(BC)患者骨质流失的风险增加。本研究评估了携带生殖系致病变异(pv)的BC幸存者的骨骼健康状况。这是一项回顾性横断面研究。我们确定了2017年2月至2022年12月在Acibadem Altunizade医院乳腺健康中心诊断出BC易感基因pv的165例BC患者。只有80例患者在诊断时接受了双能x线吸收仪(DXA)。患者年龄中位数为44岁。在80例患者中,47% (n = 38)患有BRCA1和BRCA2,而其余53% (n = 42)患有其他pv,我们称之为非brca。21例BRCA患者和6例非BRCA pv患者接受了降低风险的双侧输卵管卵巢切除术(RRBSO) (p <0.001)。在68个月的随访期间,共有53%的患者骨质减少,11%的患者骨质疏松。根据突变类型,在BRCA1和BRCA2患者中,47%出现骨质减少,11%出现骨质疏松症。在非brca患者中,57%有骨质减少,12%有骨质疏松(p >0.05)。在这项研究中,我们发现BRCA和非BRCA突变的患者骨质减少和骨质疏松的发生率相似。这对于非brca突变携带者尤其重要,因为这方面的数据不足。
{"title":"Evaluation of bone health in breast cancer patients with germline pathogenic","authors":"","doi":"10.22514/ejgo.2023.090","DOIUrl":"https://doi.org/10.22514/ejgo.2023.090","url":null,"abstract":"Patients with breast cancer (BC) have an increased risk of bone loss due to both the cancer itself and the side effects of antineoplastic therapies. This study evaluated the bone health of survivors of BC with germline pathogenic variants (PVs). This is a retrospective cross-sectional study. We identified 165 BC patients in whom PVs in BC susceptibility genes were diagnosed between February 2017 and December 2022 at our breast health center in Acibadem Altunizade Hospital. Only 80 patients underwent dual-energy X-ray absorptiometry (DXA) at the time of diagnosis. The median patient age was 44 years. Of 80 patients, 47% had (n = 38) had BRCA1 and BRCA2, while the remaining 53% (n = 42) had other PVs, which we refer to as non-BRCA. Risk-reducing bilateral salpingo-oophorectomy (RRBSO) was performed in 21 patients with BRCA and 6 patients with non-BRCA PVs patients (p < 0.001). At the 68-months follow up period, a total of 53% had osteopenia, and 11% had osteoporosis. According to the mutation type, among patients with BRCA1 and BRCA2, 47% exhibited osteopenia and 11% had osteoporosis. In non-BRCA, 57% had osteopenia and 12% had osteoporosis (p > 0.05). In this study, we showed that patients with BRCA and non-BRCA mutations have similar rates of osteopenia and osteoporosis. This is particularly important for non-BRCA mutation carriers, because there is insufficient data on this subject.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"73 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136366307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bioinformatics analysis of the diagnostic significance and functions of RDH5 in breast cancer RDH5在乳腺癌诊断意义及功能的生物信息学分析
4区 医学 Q4 OBSTETRICS & GYNECOLOGY Pub Date : 2023-01-01 DOI: 10.22514/ejgo.2023.054
Objective: RDH5 (Retinol dehydrogenase 5) is one of the member of the short-chain dehydrogenase/reductase (SDR) family and plays a critical role in a variety of tumor processes. In this study, we analyzed the expression, diagnostic significance and gene function of RDH5 in breast cancer. Methods: The Gene Expression Profiling Interactive Analysis (GEPIA) database was used to determine the diagnostic and prognostic value of RDH5 and the University of Alabama at Birmingham (UALCAN) database analyzed its expression in different subtypes, clinical stages and altered signal pathways in breast cancer. Then we explored the co-expression gene of RDH5 in breast cancer and constructed its corresponding network through the cBioPortal database. The String database was used to determine its interactions with other proteins. Results: RDH5 expression was differentiated in various tumours compared to normal tissue, and was down-regulated in breast cancer tissue and different subtypes of breast cancer. There was no correlation between RDH5 and the survival of breast cancer. RDH5 expression was significantly associated with different clinical parameters. Additionally, the protein expression of RDH5 in breast cancer with altered pathways indicated it was closely associated with the SWI-SNF (switching/sucrose non-fermenting) complex status and the mammalian Target of Rapamycin (mTOR), WNT (Wingless/Integrated), MYC/MYCN (Myelocytomatosis oncogene/euroblastoma derived MYC), RTK (receptor Tyrosine kinases), and p53/Rb (tumor protein p53/Retinoblastoma) pathways. Interaction analysis with RDH5 and its co-expression genes showed that its main related functions were ethanol oxidation, regulation of heart contraction and negative regulation of tumor necrosis factor. Lastly, the Protein-protein interaction (PPI) of RDH5 showed that the most relevant Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were retinol metabolism, vitamin digestion and absorption and metabolic pathways. Conclusion: These results implied that RDH5 might be a larvaceous diagnostic biomarker for breast cancer and was closely associated with its metabolism. However, more studies are needed to confirm our findings and support the clinical importance of RDH5 in breast cancer.
目的:RDH5 (Retinol dehydrogenase 5)是短链脱氢酶/还原酶(SDR)家族成员之一,在多种肿瘤过程中起关键作用。本研究分析RDH5在乳腺癌中的表达、诊断意义及基因功能。方法:采用基因表达谱交互分析(GEPIA)数据库确定RDH5的诊断和预后价值,阿拉巴马大学伯明翰分校(UALCAN)数据库分析RDH5在乳腺癌不同亚型、临床分期和信号通路改变中的表达。然后我们通过cBioPortal数据库探索RDH5在乳腺癌中的共表达基因,并构建相应的网络。String数据库用于确定其与其他蛋白质的相互作用。结果:与正常组织相比,RDH5在各种肿瘤中表达均有分化,在乳腺癌组织及不同亚型乳腺癌中表达均下调。RDH5与乳腺癌的生存率没有相关性。RDH5表达与不同临床参数有显著相关性。此外,RDH5在通路改变的乳腺癌中的蛋白表达表明,它与SWI-SNF(开关/蔗糖非发酵)复合物状态以及哺乳动物雷帕霉素靶蛋白(mTOR)、WNT(无翼/整合)、MYC/MYCN(髓细胞瘤癌基因/神经母细胞瘤衍生MYC)、RTK(受体酪氨酸激酶)和p53/Rb(肿瘤蛋白p53/视网膜母细胞瘤)通路密切相关。与RDH5及其共表达基因的互作分析表明,其主要相关功能为乙醇氧化、调节心脏收缩和负调控肿瘤坏死因子。最后,RDH5蛋白-蛋白相互作用(PPI)表明,与京都基因基因组百科全书(KEGG)最相关的途径是视黄醇代谢途径、维生素消化吸收途径和代谢途径。结论:RDH5可能是一种重要的乳腺癌诊断生物标志物,与RDH5的代谢密切相关。然而,需要更多的研究来证实我们的发现,并支持RDH5在乳腺癌中的临床重要性。
{"title":"Bioinformatics analysis of the diagnostic significance and functions of RDH5 in breast cancer","authors":"","doi":"10.22514/ejgo.2023.054","DOIUrl":"https://doi.org/10.22514/ejgo.2023.054","url":null,"abstract":"Objective: RDH5 (Retinol dehydrogenase 5) is one of the member of the short-chain dehydrogenase/reductase (SDR) family and plays a critical role in a variety of tumor processes. In this study, we analyzed the expression, diagnostic significance and gene function of RDH5 in breast cancer. Methods: The Gene Expression Profiling Interactive Analysis (GEPIA) database was used to determine the diagnostic and prognostic value of RDH5 and the University of Alabama at Birmingham (UALCAN) database analyzed its expression in different subtypes, clinical stages and altered signal pathways in breast cancer. Then we explored the co-expression gene of RDH5 in breast cancer and constructed its corresponding network through the cBioPortal database. The String database was used to determine its interactions with other proteins. Results: RDH5 expression was differentiated in various tumours compared to normal tissue, and was down-regulated in breast cancer tissue and different subtypes of breast cancer. There was no correlation between RDH5 and the survival of breast cancer. RDH5 expression was significantly associated with different clinical parameters. Additionally, the protein expression of RDH5 in breast cancer with altered pathways indicated it was closely associated with the SWI-SNF (switching/sucrose non-fermenting) complex status and the mammalian Target of Rapamycin (mTOR), WNT (Wingless/Integrated), MYC/MYCN (Myelocytomatosis oncogene/euroblastoma derived MYC), RTK (receptor Tyrosine kinases), and p53/Rb (tumor protein p53/Retinoblastoma) pathways. Interaction analysis with RDH5 and its co-expression genes showed that its main related functions were ethanol oxidation, regulation of heart contraction and negative regulation of tumor necrosis factor. Lastly, the Protein-protein interaction (PPI) of RDH5 showed that the most relevant Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were retinol metabolism, vitamin digestion and absorption and metabolic pathways. Conclusion: These results implied that RDH5 might be a larvaceous diagnostic biomarker for breast cancer and was closely associated with its metabolism. However, more studies are needed to confirm our findings and support the clinical importance of RDH5 in breast cancer.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"44 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136115080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European journal of gynaecological oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1